Oruka Therapeutics, Inc. (ORKA)
NASDAQ: ORKA · Real-Time Price · USD
73.99
-2.40 (-3.14%)
At close: Apr 28, 2026, 4:00 PM EDT
74.25
+0.26 (0.35%)
After-hours: Apr 28, 2026, 7:58 PM EDT
Oruka Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 |
| Selling, General & Admin | 21.41 | 14.25 |
| Research & Development | 100.64 | 81.01 |
| Operating Expenses | 122.05 | 95.26 |
| Operating Income | -122.05 | -95.26 |
| Interest Expense | - | -1.6 |
| Interest & Investment Income | 16.63 | 6.4 |
| Other Non Operating Income (Expenses) | -0.01 | 0 |
| EBT Excluding Unusual Items | -105.43 | -90.46 |
| Other Unusual Items | - | -0.87 |
| Pretax Income | -105.43 | -91.34 |
| Net Income | -105.43 | -91.34 |
| Preferred Dividends & Other Adjustments | -21.12 | -20.39 |
| Net Income to Common | -84.31 | -70.95 |
| Shares Outstanding (Basic) | 46 | 17 |
| Shares Outstanding (Diluted) | 46 | 17 |
| Shares Change (YoY) | 171.69% | - |
| EPS (Basic) | -1.85 | -4.23 |
| EPS (Diluted) | -1.85 | -4.23 |
| Free Cash Flow | -88.42 | -63.3 |
| Free Cash Flow Per Share | -1.94 | -3.77 |
| EBITDA | -121.97 | -95.23 |
| D&A For EBITDA | 0.08 | 0.03 |
| EBIT | -122.05 | -95.26 |
Source: S&P Capital IQ. Standard template.
Financial Sources.